Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy Publisher Pubmed



Masjedi A^{1, 2} ; Ahmadi A³ ; Ghani S⁴ ; Malakotikhah F⁵ ; Nabi Afjadi M⁶ ; Irandoust M⁷ ; Karoon Kiani F⁷ ; Heydarzadeh Asl S⁷ ; Atyabi F⁸ ; Hassannia H⁹ ; Hojjatfarsangi M^{10, 11} ; Namdar A¹² ; Ghalamfarsa G¹³ ; Jadidiniaragh F^{1, 14}
Source: Nanomedicine: Nanotechnology# Biology# and Medicine Published:2020

Abstract

Overexpression of adenosine in the tumor region leads to suppression of various immune cells, particularly T cells through ligation with adenosine 2a receptor (A2aR). In this study, we intended to increase the efficacy of tumor lysate-loaded DC vaccine by silencing the expression of A2aR on T cells through the application of A2aR-specific siRNA-loaded PEG-chitosan-lactate (PCL) nanoparticles (NPs) in the 4T1 breast tumor-bearing mice. Combination therapy by DC vaccine and siRNA-loaded NPs markedly induced tumor regression and increased survival time of mice. These ameliorative effects were partly via downregulation of immunosuppressive cells, increased function of cytotoxic T lymphocytes, and induction of immune-stimulatory cytokines. Moreover, combination therapy could markedly suppress angiogenesis and metastasis processes. These results imply the efficacy of novel combination therapy for the treatment of breast cancer by using A2aR siRNA-loaded NPs and DC vaccine which can be translated into the initial phase of clinical trials in the near future. © 2020 Elsevier Inc.